Investors Press Releases Nov 02 2026 Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Read More Oct 21 2026 Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto Read More Oct 16 2026 Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease Read More btn News View All Events & Presentations More events are coming soon. btn Events View All Interim Reports Interim Results for the Six Months Ended 30 June 2026 758.9 KB bth Interim Reports View All Annual Reports 20 F - Annual Report for the year ended 31 December 2025 2 MB btn ARs View All Annual General Meeting 2025 AGM Results 60.5 KB btn AGM View All Stock Quote Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 Week Low Stock Chart
Nov 02 2026 Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Read More
Oct 21 2026 Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto Read More
Oct 16 2026 Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease Read More